医学院 ENGLISH 江苏大学首页

当前位置 首页 >> 师资队伍 >> 教师风采 >> 正文

张徐


江苏大学,医学院,副教授,硕导
江苏省“青蓝工程”青年骨干教师
江苏大学“青年学术带头人”
江苏省“优博”获得者

主讲课程:
医学分子生物学;药学分子生物学;分子生物学检验

研究方向
肿瘤分子生物学;干细胞生物学;分子诊断学

教育经历:
2012/05 - 2013/09,美国Texas Tech Univ,肿瘤分子生物学,博士后
2008/09 - 2011/12,江苏大学,临床检验诊断学,博士
2006/09 - 2008/07,江苏大学,临床检验诊断学,硕士
2001/09 - 2006/07,江苏大学,医学检验,学士

工作经历:
2015/05 - 至今,江苏省检验医学重点实验室,分子生物学检验研究室主任
2015/05 - 至今,江苏大学医学院,分子生物学及检验教研室,副主任
2015/05 - 至今,江苏大学医学院,副教授
2013/01 - 至今,江苏大学医学院,硕导
2012/05 - 2013/09,美国得克萨斯理工大学药学院,药理学系,博士后
2010/08 - 2012/04,美国得克萨斯理工大学药学院,药理学系,访问学者
2009/05 - 2010/07,美国阿拉巴马大学医学院,药理/毒理学系,访问学者

主持、参加或完成科研项目及人才计划项目情况:
1)国家自然科学青年基金,胃癌微环境MSC调节中性粒细胞极化作用及分子机制 (81201660) (2013.01-2015.12),负责人,23万元
2)江苏省自然科学基金面上项目,中性粒细胞调节MSC活化促胃癌生长作用和机制研究 (BK20141303) (2014.07-2017.06),负责人,10万元
3)镇江市重点研发(社会发展)计划,SALL4作为胃癌早期诊断和治疗新靶点研究 (SH2015034) (2015.08-2017.07),负责人,2万元
4)江苏省检验医学重点实验室开放基金,干细胞因子SALL4在胃癌诊疗中的应用和机制研究 (JSKLM-2014-006) (2015.01-2016.12),负责人,1.5万元
5)江苏省教育厅“青蓝工程”项目,胃癌微环境MSC调节中性粒细胞极化作用和机制研究 (2014.06-2017.06),负责人,2万元
6)江苏大学“青年骨干教师培养工程”项目,中性粒细胞极化与胃癌研究 (2014.06-2018.06),负责人,6万元
7)江苏大学高级人才启动基金,胃癌MSC调节中性粒细胞作用及机制研究 (13JDG086) (2013.01-2014.12),负责人,5万元
8)国家自然科学基金面上项目,MSC来源exosomes在急性心肌梗死损伤修复中的作用及机制 (81270214) (2013.01-2016.12),主要参与者 (3/8),70万
9)江苏省高校自然科学研究重大项目,急性肾损伤标志物miR-146b的应用和机制研究 (15KJA320001) (2015.07-2018.06),主要参与者 (3/8),30万
10)江苏省高校优秀科技创新团队,干细胞及相关分子的基础与临床(2014.07-2017.06),主要参与者 (5/10),30万
11)江苏省自然科学基金面上项目,脐带间质干细胞因子SALL4在胃癌诊断与治疗中的实验研究 (BK2012709) (2012.07-2015.06),主要完成人 (2/7),10万元
12)国家自然科学基金重大研究计划,间质干细胞在非可控性炎症导致胃癌发生与恶性转化中的作用及机制 (91129718) (2012.01-2014.12),主要完成人(4/10),80万元 
13)国家自然科学青年基金,小鼠骨髓MSC调控单核/巨噬细胞修复肝损伤的机制研究 (81000181) (2011.01-2013.12),主要完成人 (2/8),20万元
14)国家自然科学基金面上项目,GC-MSC和癌组织来源的MicroRNAs在胃癌诊治中的作用 (81071421) (2011.01-2013.12),主要完成人 (4/9),36万元
15)江苏省科技支撑计划,脐带间质干细胞外切体(exosome)的制备及应用研究 (BE2010703) (2010.04-2013.12),主要完成人 (5/12),20万元
16)国家自然科学基金,脐带间质干细胞介导的肾功能修复及机制研究(30840053) (2009.01-2009.12),主要完成人(4/11),9万元
17)江苏省自然科学基金面上项目,骨髓间质干细胞与肿瘤微环境及靶向治疗(BK2008232) (2009.1-2011.12),主要完成人(9/10),9万元
18)江苏省自然科学基金重点项目,骨髓间质干细胞与其致瘤干细胞分子差异及靶向治疗研究 (BK2007705) (2007.07-2009.12),主要完成人(4/10),30万元

主要发表SCI论文(#第一作者;*通讯作者):
1)Zhang X, Wang W, Wang H, Wang M, Xu W, Zhang R. Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loops. Oncogene. 2013, 32(22):2782-91. (IF:8.459)
2)Zhang X, Zhang Z, Cheng J, Li M, Wang W, Xu W, Wang H, Zhang R. Transcription factor NFAT1 activates the mdm2 oncogene independent of p53. J Biol Chem. 2012, 287(36):30468-76. (IF:4.573)
3)Zhang X#,*, Yuan X, Zhu W, Qian H, Xu W. SALL4: an emerging cancer biomarker and target. Cancer Lett. 2015, 357(1):55-62. (IF:5.621)
4)Zhang X, Yuan X, Shi H, Wu L, Qian H, Xu W. Exosomes in cancer: small particle, big player. J Hematol Oncol. 2015, 8:83. (IF:4.812)
5)Zhang X, Xu W, Qian H, Zhu W, Zhang R. Mesenchymal stem cells modified to express lentivirus TNF-α Tumstatin (45-132) inhibit the growth of prostate cancer. J Cell Mol Med. 2011, 15(2):433-44. (IF:4.014)
6)Zhang X, Zhang L, Xu W, Qian H, Ye S, Zhu W, Cao H, Yan Y, Li W, Wang M, Wang W, Zhang R. Experimental therapy for lung Cancer: umbilical cord-derived mesenchymal stem cell-mediated interleukin-24 delivery. Curr Cancer Drug Targets. 2013, 13(1):92-102. (IF:3.522)
7)Zhu Q, Zhang X#,*, Zhang L, Li W, Wu H, Yuan X, Mao F, Wang M, Zhu W, Qian H, Xu W. The IL-6–STAT3 axis mediates a reciprocal crosstalk between cancer-derived mesenchymal stem cells and neutrophils to synergistically prompt gastric cancer progression. Cell Death Dis. 2014, 5:e1295. (IF:5.014)
8)Yang T, Zhang X#, Wang M, Zhang J, Huang F, Cai J, Zhang Q, Mao F, Zhu W, Qian H, Xu W. Activation of mesenchymal stem cells by macrophages prompts human gastric cancer growth through NF-κB pathway. PLoS One. 2014, 9(5): e97569. (IF:3.534)
9)Qian H, Zhang X#, Xu W, Zhu W, Cao H, Chen Y, Xu X, Wang M, Xie Y, Sun J. Lentivirus-modified human umbilical cord mesenchymal stem cells maintains their pluripotency. Biotechnol Appl Biochem. 2010, 55(1):53-62. (IF:1.322)
10)Wu L, Zhang X#, Zhang B, Shi H, Yuan X, Sun Y, Pan Z, Qian H, Xu W. Exosomes derived from gastric cancer cells activate NF-κB pathway in macrophages to promote cancer progression. Tumor Biol, 2016, in press. (IF:3.611)
11)Fu H, Yang H, Zhang X*, Xu W. The emerging roles of exosomes in tumor-stroma interaction. J Cancer Res Clin Oncol. 2016, in press. (IF:3.009)
12)Yang H, Fu H, Zhang X*, Xu W. Exosomal non-coding RNAs: a promising cancer biomarker. Clin Chem Lab Med. 2016, in press. (IF:2.707)
13)Fu M, Zou C, Pan L, Liang W, Qian H, Xu W, Jiang P, Zhang X*. Long noncoding RNAs in digestive system cancers: functional roles, molecular mechanisms, and clinical implications. Oncol Reports, 2016, in press. (IF:2.301)
14)Xu X, Zhang X, Wang S, Qian H, Zhu W, Cao H, Wang M, Chen Y, Xu W. Isolation and comparison of mesenchymal stem-like cells from human gastric cancer and adjacent non-cancerous tissues. J Cancer Res Clin Oncol. 2011, 137(3):495-504. (IF:3.009)
15)Wang W, Zhang X, Qin J, Voruganti S, Nag SA, Wang M, Wang H, Zhang R. Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2. PLoS One. 2012, 7(7):e41586. (IF:3.534)
16)Nag S, Zhang X, Srivenugopal KS, Wang MH, Wang W, Zhang R. Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet? Curr Med Chem. 2014, 21(5):553-74. (IF:3.715)
17)Wang W, Nag S, Zhang X, Wang MH, Wang H, Zhou J, Zhang R. Ribosomal Proteins and Human Diseases: Pathogenesis, Molecular Mechanisms, and Therapeutic Implications. Med Res Rev. 2015, 35(2):225-85. (IF:8.131)
18)Ji R, Zhang B, Zhang X, Xue J, Yuan X, Yan Y, Wang M, Zhu W, Qian H, Xu W. Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer. Cell Cycle. 2015, 14(15):2473-83. (IF:5.006)
19)Qian Q, Qian H, Zhang X, Zhu W, Yan Y, Ye S, Peng X, Li W, Xu Z, Sun L, Xu W. 5-Azacytidine induces cardiac differentiation of human umbilical cord-derived mesenchymal stem cells by activating extracellular regulated kinase. Stem Cells Dev. 2012, 21(1):67-75. (IF:4.202)
20)Zhang B, Wang M, Gong A, Zhang X, Wu X, Zhu Y, Shi H, Wu L, Zhu W, Qian H, Xu W. HucMSC-exosome mediated-Wnt4 signaling is required for cutaneous wound healing. Stem Cells. 2015, 33(7):2158-68. (IF:7.133)
21)Zhang B, Wu X, Zhang X, Sun Y, Yan Y, Shi H, Zhu Y, Wu L, Pan Z, Zhu W, Qian H, Xu W. Human Umbilical Cord Mesenchymal Stem Cell Exosomes Enhance Angiogenesis Through the Wnt4/β-Catenin Pathway. Stem Cells Transl Med. 2015, 4(5):513-22.  (IF:3.596) 
22)Li W, Zhou Y, Yang J, Zhang X, Zhang H, Zhang T, Zhao S, Zheng P, Huo J, Wu H. Gastric cancer-derived mesenchymal stem cells prompt gastric cancer progression through interleukin-8. J Exp Clin Cancer Res. 2015, 34:52.  (IF:3.271)
23)Xue J, Zhu Y, Sun Z, Ji R, Zhang X, Xu W, Yuan X, Zhang B, Yan Y, Yin L, Xu H, Zhang L, Zhu W, Qian H. Tumorigenic hybrids between mesenchymal stem cells and gastric cancer cells enhanced cancer proliferation, migration and stemness. BMC Cancer. 2015, 15:793. (IF:3.362)
24)Xu H, Qian H, Zhu W, Zhang X, Yan Y, Mao F, Wang M, Xu H, Xu W. Mesenchymal stem cells relieve fibrosis of Schistosoma japonicum-induced mouse liver injury. Exp Biol Med (Maywood). 2012, 237(5):585-92.  (IF:2.226)
25)Zhu W, Huang L, Li Y, Zhang X, Gu J, Yan Y, Xu X, Wang M, Qian H, Xu W. Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Lett. 2012, 315(1):28-37.  (IF:5.016)
26)Chen Y, Qian H, Zhu W, Zhang X, Yan Y, Ye S, Peng X, Li W, Xu W. Hepatocyte growth factor modification promotes the amelioration effects of human umbilical cord mesenchymal stem cells on rat acute kidney injury. Stem Cells Dev. 2011, 20(1):103-13. (IF:4.202)
27)Xu X, Qian H, Zhu W, Zhang X, Yan Y, Wang M, Xu W. Isolation of cancer stem cells from transformed human mesenchymal stem cell line F6. J Mol Med (Berl). 2010, 88(11):1181-90. (IF:4.739)
28)Gu J, Qian H, Shen L, Zhang X, Zhu W, Huang L, Yan Y, Mao F, Zhao C, Shi Y, Xu W. Gastric Cancer Exosomes Trigger Differentiation of Umbilical Cord Derived Mesenchymal Stem Cells to Carcinoma-Associated Fibroblasts through TGF-β/Smad Pathway. PLoS One. 2012, 7(12):e52465. (IF:3.534)
29)Li T, Yan Y, Wang B, Qian H, Zhang X, Shen L, Wang M, Zhou Y, Zhu W, Li W, Xu W. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev. 2012, 22(6):845-54. (IF:4.202)
30)Gao S, Mao F, Zhang B, Zhang L, Zhang X, Wang M, Yan Y, Yang T, Zhang J, Zhu W,  Qian H,  Xu W. Mouse bone marrow derived mesenchymal stem cells induce macrophage M2 polarization through the NF-κB and STAT3 pathways. Exp Biol Med (Maywood). 2014, 239(3):366-75. (IF:2.226)
31)Cao H, Qian H, Xu W, Zhu W, Zhang X, Chen Y, Wang M, Yan Y, Xie Y. Mesenchymal stem cells derived from human umbilical cord ameliorate ischemia/reperfusion-induced acute renal failure in rats. Biotechnol Lett. 2010, 32(5):725-32. (IF:1.736)
32)Wang M, Gu H, Qian H, Zhu W, Zhao C, Zhang X, Tao Y, Zhang L, Xu W. miR-17-5p/20a are important markers for gastric cancer and murine double minute 2 participates in their functional regulation. Eur J Cancer. 2013, 49(8):2010-21. (IF:4.819)
33)Yan Y, Xu W, Qian H, Zhu W, Mao F, Zhang X. Tumstatin45-132-TNFalpha suppresses tumour growth through anti-angiogenic effects and cytotoxicity. Biotechnol Appl Biochem. 2010, 56(3):119-27. (IF:1.322) 
34)Cao H, Xu W, Qian H, Zhu W, Yan Y, Zhou H, Zhang X, Xu X, Li J, Chen Z, Xu X. Mesenchymal stem cell-like cells derived from human gastric cancer tissues. Cancer Lett. 2009, 274(1):61-71. (IF:5.016)
35)Peng X, Xu H, Zhou Y, Wang B, Yan Y, Zhang X, Wang M, Gao S, Zhu W, Xu W, Qian H. Human umbilical cord mesenchymal stem cells attenuate cisplatin-induced acute and chronic renal injury. Exp Biol Med (Maywood). 2013, 238(8):960-70. (IF:2.226)
36)Zhang Q, Wang M, Huang F, Yang T, Cai J, Zhang X, Zhu W, Qian H, Xu W. H. pylori infection-induced MSC differentiation into CAFs promotes epithelial-mesenchymal transition in gastric epithelial cells. Int J Mol Med. 2013, 32(6):1465-73. (IF:1.88)
37)Zhang L, Xu Z, Xu X, Zhang B, Wu H, Wang M, Zhang X, Yang T, Cai J, Yan Y,  Mao F, Zhu W, Shao Q, Qian H, Xu W. SALL4, a novel marker for human gastric carcinogenesis and metastasis. Oncogene. 2014, 33(48):5491-500. (IF:8.559) 
38)Wang M, Zhao C, Shi H, Zhang B, Zhang L, Zhang X, Wang S, Wu X, Yang T, Huang F, Cai J, Zhu Q, Zhu W, Qian H, Xu W. Deregulated microRNAs in gastric cancer tissue-derived mesenchymal stem cells: novel biomarkers and a mechanism for gastric cancer. Br J Cancer. 2014, 110(5):1199-210. (IF:4.817)
39)Huang F, Wang M, Yang T, Cai J, Zhang Q, Sun Z, Zhang X, Zhu W, Qian H, Xu W. Gastric cancer-derived MSC-secreted PDGF-DD promotes gastric cancer progression. J Cancer Res Clin Oncol. 2014, 140(11):1835-48. (IF:3.009)
40)Wang M, Cai J, Huang F, Zhu M, Zhang Q, Yang T, Zhang X, Qian H, Xu W. Pre-treatment of human umbilical cord-derived mesenchymal stem cells with interleukin-6 abolishes their growth-promoting effect on gastric cancer cells. Int J Mol Med. 2015, 35(2):367-75. (IF:1.88)
41)Cai J, Wang M, Zhu M, Zhang Q, Zhang X, Yan Y, Qian H, Xu W. N methyl N nitro N' nitrosoguanidine induces the expression of CCR2 in human gastric epithelial cells promoting CCL2 mediated migration. Mol Med Rep. 2015 Dec 7. doi: 10.3892/mmr.2015.4650. (IF:1.554)
42)Zhu Y, Zhang B, Gong A, Fu H, Zhang X, Shi H, Sun Y, Wu L, Pan Z, Mao F, Zhu W, Qian H, Xu W. Anti-cancer drug 3,3'-diindolylmethane activates Wnt4 signaling to enhance gastric cancer cell stemness and tumorigenesis. Oncotarget. 2016 Feb 24. doi: 10.18632/oncotarget.7684. (IF:6.359) 
43)Wang W, Ao L, Rayburn ER, Xu H, Zhang X, Zhang X, Nag SA, Wu X, Wang MH, Wang H, Van Meir EG, Zhang R. KCN1, a Novel Synthetic Sulfonamide Anticancer Agent: In Vitro and In Vivo Anti-Pancreatic Cancer Activities and Preclinical Pharmacology. PLoS One. 2012, 7(9):e44883. (IF:3.534)
44) Ezell SJ, Li H, Xu H, Zhang X, Gurpinar E, Zhang X, Rayburn ER, Sommers CI, Yang X, Velu SE, Wang W, Zhang R. Preclinical pharmacology of BA-TPQ, a novel synthetic iminoquinone anticancer agent. Mar Drugs. 2010, 8(7):2129-41.  (IF:3.512)
45)Li H, Ezell SJ, Zhang X, Wang W, Xu H, Rayburn ER, Zhang X, Gurpinar E, Yang X, Sommers CI, Velu SE, Zhang R. Development and validation of an HPLC method for quantitation of BA-TPQ, a novel iminoquinone anticancer agent, and an initial pharmacokinetic study in mice. Biomed Chromatogr. 2011, 25(5):628-34. (IF:1.662)
46)Zhang X, Xu H, Zhang X, Voruganti S, Murugesan S, Nadkarni DH, Velu SE, Wang M, Wang W, Zhang R. Preclinical Evaluation of Anticancer Efficacy and Pharmacological Properties of FBA-TPQ, a Novel Synthetic Makaluvamine Analog. Mar Drugs. 2012, 10:1138-1155. (IF:3.512)
47)Rayburn E, Wang W, Li M, Zhang X, Xu H, Li H, Qin JJ, Jia L, Covey J, Lee M, Zhang R. Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent. Cancer Chemother Pharmacol. 2012, 69(6):1423-31. (IF:2.571)

主要发表中文论文(#第一作者;*通讯作者)
1)张徐*,徐梦,刘叶,顾笑笑,钱晖,许文荣. 干细胞因子Nanog在肿瘤中的研究进展[J]. 2016, 43 (04): 295-299.  (中文核心期刊)
2)张徐,王梦瑶,徐捡,王勇,钱晖,许文荣. 长链非编码RNA 在乳腺癌中的研究进展[J]. 临床检验杂志, 2015, 33(6):454-456. (中文核心期刊)
3)张徐,许文荣. 肿瘤相关中性粒细胞研究进展 [J]. 临床检验杂志, 2013, 31(12):929-931. (中文核心期刊)

专利申请: 
1)张斌,许文荣,钱晖,张徐,王梅,吴晓丹,朱艳华,史惠. 小型动物皮肤烫伤装置.  实用新型专利,申请号:CN201420060187.X,已授权.
2)张斌, 许文荣, 钱晖, 朱伟, 张徐, 王梅 ,吴晓丹,朱艳华,史惠. 大鼠真皮间质干细胞的培养方法.  发明专利,申请号:CN201410085659.1
3)钱晖,张斌,丁小青,许文荣,严永敏,王梅,朱伟,毛飞,张徐,叶惠慧. 间质干细胞体内突变肿瘤细胞株B6及其应用. 发明专利,申请号: 201410394011.2.

获奖情况:
1)张徐. “TNFα-Tumstatin融合基因修饰间质干细胞及核糖体蛋白S25调节p53抗肿瘤作用”,2013年度江苏省优秀博士论文奖。
2)张徐. “核糖体蛋白S25-MDM2-p53信号调节通路的发现”,2013年度镇江市优秀科技论文特等奖。